Shoman is part of the investment team at Foresite Capital, and is focused on opportunities in life sciences and healthcare technology.
Shoman came to Foresite from Synthego, a life sciences company building automated platforms for CRISPR genome editing. At Synthego he managed strategy and business development across genome editing technologies, discovery platforms, and therapeutics. Prior to Synthego, Shoman held roles in strategy and finance at DaVita, a healthcare company serving over 200,000 patients with kidney disease. At DaVita,
In addition to his work with Foresite Capital, Shoman is a member of the strategic alliances team at the Rare Genomics Institute, a non-profit dedicated to helping rare disease patients and their families find a cure. Shoman received his B.E. in Biomedical Engineering from Vanderbilt University.
Shoman is attending / has attended:
Sign up now to stay up-to-date with all our events, news, deals and more!